ACM
NVCR icon

Atika Capital Management’s NovoCure NVCR Stock Holding History

Atika Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-25,200
Closed -$365K – 68
2016
Q1 		$365K Buy
+25,200
New +$362K 0.22% 43

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Atika Capital Management's NVCR Position: Q1 2020 in Review

Atika Capital Management sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 32,000 shares — an estimated $2.7M sold.

Atika Capital Management first reported a position in NVCR in Q2 2018 and held it in 7 quarters. The position peaked at $10.3M in Q3 2018. 272 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

  • Atika Capital Management reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
  • Atika Capital Management sold 32,000 NovoCure shares in Q1 2020, an estimated $2.7M.
  • Atika Capital Management first reported a position in NovoCure in Q2 2018 and held it in 7 quarters.
  • Atika Capital Management's NovoCure position peaked at $10.3M in Q3 2018.
  • 272 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Atika Capital Management's 13F filing for Q1 2020, filed 14 May 2020.